Poor
Needs Review
Patient Risk:
Moderate
Summary
Most claims are non-label cost/generic-manufacturer statements not addressed in the provided INZIRQO prescribing information; multiple safety-related claims are only partially supported (label does not explicitly include some effects as stated), and several omissions are likely material for accurate label-consistent safety communication.
Category Scores
Accurate Statements
Hydrochlorothiazide is used for high blood pressure.
Supported by INZIRQO Section 1.1 Hypertension (treatment of hypertension in adult and pediatric patients, to lower blood pressure).
Hydrochlorothiazide is used for fluid retention.
Supported by INZIRQO Section 1.2 Edema (treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease including nephrotic syndrome).
Hydrochlorothiazide can cause low potassium.
Supported by INZIRQO Section 5.2 Electrolyte Abnormalities (potentially symptomatic hypokalemia; dose dependent).
Hydrochlorothiazide can cause low sodium.
Supported by INZIRQO Section 5.2 Electrolyte Abnormalities (hyponatremia).
Low potassium or low sodium may require blood tests or supplements.
Partially supported by INZIRQO Section 5.2 (monitor and correct serum electrolytes prior to use and monitor periodically). The label does not specifically mention 'supplements'.
Hydrochlorothiazide can increase blood sugar in some patients.
Supported by INZIRQO Section 5.3 Metabolic Disturbances (may increase blood sugar levels, affect diabetes control).
Hydrochlorothiazide can increase cholesterol in some patients.
Supported by INZIRQO Section 5.3 Metabolic Disturbances (may raise serum levels of cholesterol and triglycerides).
Hydrochlorothiazide can cause higher uric acid.
Supported by INZIRQO Section 5.3 Metabolic Disturbances (may raise serum uric acid level; may cause or exacerbate hyperuricemia).
Hydrochlorothiazide can cause low blood pressure.
Supported in concept only: INZIRQO Section 5.1 discusses hypovolemia from diuretics which may precipitate acute kidney injury, but the provided excerpt does not explicitly state 'low blood pressure'. (See unsupported/omission below for explicitness.)
Unsupported Statements
Hydrochlorothiazide is a low-cost, widely available generic medicine.
Not addressed in the provided INZIRQO prescribing information (no cost/availability statements).
Hydrochlorothiazide is off-patent.
Not addressed in the provided INZIRQO prescribing information.
Hydrochlorothiazide is sold by many manufacturers.
Not addressed in the provided INZIRQO prescribing information.
Because hydrochlorothiazide is off-patent and sold by many manufacturers, prices are usually lower than brand-name alternatives.
Not addressed in the provided INZIRQO prescribing information.
Actual price of hydrochlorothiazide varies depending on whether you buy a brand versus generic.
Not addressed in the provided INZIRQO prescribing information.
Generic hydrochlorothiazide is usually the low-cost option.
Not addressed in the provided INZIRQO prescribing information.
The dose and tablet strength affect hydrochlorothiazide price.
Not addressed in the provided INZIRQO prescribing information, and the provided label describes a suspension (10 mg/mL) rather than 'tablet strength'.
The pharmacy and your location affect hydrochlorothiazide price.
Not addressed in the provided INZIRQO prescribing information.
Supply size affects hydrochlorothiazide price (e.g., a 30-day versus 90-day supply).
Not addressed in the provided INZIRQO prescribing information.
Insurance, a pharmacy discount card, or a patient assistance program can affect hydrochlorothiazide price.
Not addressed in the provided INZIRQO prescribing information.
Asking for generic hydrochlorothiazide (confirming you’re getting the generic product) is a common cost-saver.
Not addressed in the provided INZIRQO prescribing information.
Comparing prices at different pharmacies is a common cost-saver for hydrochlorothiazide.
Not addressed in the provided INZIRQO prescribing information.
Using a discount program or prescription savings card if paying cash is a common cost-saver for hydrochlorothiazide.
Not addressed in the provided INZIRQO prescribing information.
Asking about a longer supply (e.g., 90-day fills) can reduce per-month costs for hydrochlorothiazide if insurance/plan reduces per-month costs.
Not addressed in the provided INZIRQO prescribing information.
Switching to a different generic manufacturer of hydrochlorothiazide is an option if price is unexpectedly high.
Not addressed in the provided INZIRQO prescribing information.
Switching to a different generic manufacturer keeps the same active ingredient and dose.
Not addressed in the provided INZIRQO prescribing information.
Using a different formulation or strength of hydrochlorothiazide only makes sense if it is appropriate for the prescription.
Not addressed in the provided INZIRQO prescribing information (and is general advice not tied to specific label instructions).
Switching to a different blood-pressure medication or combination pill may make sense for a person's condition depending on health history and prior responses.
Not addressed in the provided INZIRQO prescribing information.
Hydrochlorothiazide can cause increased urination early in treatment.
Not explicitly stated in the provided excerpts. The mechanism suggests increased sodium/chloride excretion, but the label excerpt does not state 'increased urination early in treatment'.
Hydrochlorothiazide can cause dizziness.
Not explicitly stated in the provided excerpts.
Hydrochlorothiazide can cause low blood pressure.
The provided excerpts do not explicitly state hypotension/low blood pressure as an adverse effect.
Higher uric acid from hydrochlorothiazide can worsen gout in some people.
The label excerpt supports that it may precipitate gout/hyperuricemia and precipitate gout, but the provided statement frames it as 'worsen gout'; while directionally consistent, the excerpt explicitly says 'precipitate gout' rather than 'worsen gout' wording. This is treated as unsupported due to mismatch in specificity/wording.
Hydrochlorothiazide can cause higher uric acid.
Marked unsupported? (Note: This one is supported by Section 5.3; included here would be incorrect. Not included as unsupported.)
Contradictions
Important Omissions
Thiazide-specific safety counseling/risks included in the label but not mentioned in the AI response (e.g., acute angle-closure glaucoma and acute myopia—symptoms and instruction to discontinue and seek immediate medical attention; non-melanoma skin cancer counseling; discard unused suspension after 30 days post-reconstitution).
Importance:
Moderate
Label-required administration instructions for INZIRQO suspension (shake well before each use; use oral dosing syringe; bottle adapter/syringes from pharmacy).
Importance:
Moderate
Contraindications for INZIRQO (anuria; hypersensitivity to hydrochlorothiazide/ingredients; hypersensitivity to sulfonamide-derived drugs) were not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes several label-consistent metabolic/electrolyte risk statements, but it omits multiple explicit label safety counseling items and contains several unsupported general statements unrelated to the prescribing information; some adverse-effect claims are not explicitly supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Many statements are not supported by the provided INZIRQO label (especially cost/market/manufacturer switching and some adverse-effect claims). Missing several label-specific contraindications and explicit safety counseling/administration instructions.
Suggested Improvement
Limit claims to what the label excerpts support (indication, dosing/administration for INZIRQO, contraindications, and explicitly described warnings/precautions). Remove or reframe non-label cost/availability/manufacturer-switching statements. Add label-specific safety counseling (acute angle-closure glaucoma/myopia; non-melanoma skin cancer; suspension discard timeframe) and administration instructions (shake well, dosing syringe).